Xlock Biosciences, Inc.
Muskego, WI
- UEI
- LRVRYJKD2Q85
- CAGE
- 8JFN9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 17483 Schubring Dr, Muskego, WI 53150, USA
- Website
- xlockbio.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Apcbio | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Celdara Medical, LLC | Lebanon, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Orpro Therapeutics Inc. | San Diego, CA | — |
| Tango Biosciences Inc. | Chicago, IL | — |
| Biotherapeutics, Inc. | Blacksburg, VA | — |
About the company
Xlock Biosciences, Inc., a for-profit biopharmaceutical company based in Muskego, Wisconsin, is a prime recipient of Small Business Innovation Research (SBIR) Phase I and Phase II grants from the National Institutes of Health, developing engineered chemokine-based therapeutic proteins for immunotherapy and inflammatory disease treatment. The company operates exclusively as a grant recipient with no federal contracts, IDVs, or subcontract work in the source data.
Xlock's federal portfolio spans three NIH institutes with four awards totaling $5.8 million obligated. The National Institute of Arthritis and Musculoskeletal and Skin Diseases funds two grants: a Phase I award (September 2023 through August 2027) to develop CCL20LD, an engineered recombinant protein targeting the CCR6-CCL20 pathway for psoriatic arthritis treatment, and an earlier Phase I award (June 2022 through December 2023) validating the same compound for chronic graft-versus-host disease, a condition affecting up to 25,000 new U.S. patients annually. The National Cancer Institute awarded $305,368 in August 2026 (completion July 2027) to develop an engineered XCL1 protein as a cancer vaccine adjuvant, targeting improved CD8+ cytotoxic T cell recruitment into tumors with greater cancer cell specificity than existing adjuvants. The National Heart Lung and Blood Institute supported an earlier Phase I project on CCL20LD for chronic graft-versus-host disease (June 2022 through December 2023). All work is performed in Muskego, Wisconsin.
Two awards face ultimate completion within the next twenty-four months. Xlock's capability focus centers on engineered chemokine proteins designed to modulate immune cell recruitment for cancer immunotherapy and T cell-mediated inflammatory disease, with all recent activity rooted in SBIR Phase I-II translational research rather than commercial services delivery to the federal government.
Quick answers
Is Xlock Biosciences, Inc. registered in SAM.gov?
Yes. Xlock Biosciences, Inc.'s SAM.gov registration is active through March 16, 2027.
What is Xlock Biosciences, Inc.'s most recent federal award?
Xlock Biosciences, Inc.'s most recent federal grant award is Enhancing anti-tumor immunotherapy with an engineered XCL1 protein (R43CA310494), from National Cancer Institute (NIH), on August 3, 2026.
On GovTribe
See Xlock Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors